⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4932093 | 0.74 | — | — | |
| SCHEMBL5683250 | 0.73 | — | — | |
| SCHEMBL4287986 | 0.72 | HTR6 (0.49) | — | |
| SCHEMBL7469721 | 0.70 | — | — | |
| SCHEMBL3525295 | 0.70 | — | — | |
| SCHEMBL9755194 | 0.70 | — | — | |
| SCHEMBL732161 | 0.70 | — | — | |
| SCHEMBL5683854 | 0.70 | — | — | |
| SCHEMBL1515340 | 0.70 | — | — | |
| SCHEMBL12470535 | 0.68 | GPR39 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | claimed |
| EP-2672967-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-12-18 | — | — | EP | claimed |
| WO-2012109075-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2012-08-16 | — | — | WO | claimed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-2672967-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9624213-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| CN-103517710-A | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC | 2014-01-15 | — | — | CN | disclosed |
| EP-2672967-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012109075-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| CN-1227248-C | Imidazolidine derivatives, their preparation, and their use as antinflamatory agent | AVENTIS PHARMA GMBH (DE) | 2005-11-16 | — | — | CN | disclosed |
| EP-1373249-B1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTIINFLAMATORY AGENT | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| CN-1496360-A | Imidazolidine derivatives, their preparation, and their use as antinflamatory agent | ������ҽҩ�¹�����˾ | 2004-05-12 | — | — | CN | disclosed |
| US-6680333-B2 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; ANTIALLERGENS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-20 | — | — | US | disclosed |
| EP-1373249-A1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTINFLAMATORY AGENT | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002072573-A1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTINFLAMATORY AGENT. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
| US-5811422-A | USEFUL FOR TREATING VIRAL INFECTIONS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-09-22 | — | — | US | disclosed |
| US-5610294-A | VIRAL TREATMENT | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-11 | — | — | US | disclosed |